arrow
S

Shibin Zhou

Johns Hopkins University School of Medicine
H指数:49
被引数:4.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TRBC2-targeting antibody–drug conjugates for the treatment of T cell cancers

用于治疗T细胞癌症的TRBC2-targeting抗体-药物结合物

2025-12-220
PRE
Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities
2024-07-101
PRE
Cancer therapy with antibodies

用抗体治疗癌症

2024-05-1314
PRE
TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers

用于治疗T细胞癌症的TRBC1-targeting抗体-药物结合物

Nature
IF48.5
2024-03-270
PRE
Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen

疏水相互作用主导了KRAS G12V新抗原的识别

2023-08-218
OAAI
Hybrid TCR-CAR design surpasses conventional CARs and patient-derived TCRs in targeting an ultra-low-density neoantigen
2023-04-140
PRE
The rapid and highly parallel identification of antibodies with defined biological activities by SLISY

通过slissy快速,高度平行地鉴定具有确定生物学活性的抗体

2023-01-031
OAAI
TCR-mimic bispecific antibodies to target the HIV-1 reservoir

TCR模拟双特异性抗体靶向HIV-1库

2022-04-0816
OAAI
Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens

靶向HLA限制性新抗原的嵌合抗原受体的结构工程

2021-09-0625
OAAI
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers

anti-PD-1-treated肺癌中新抗原特异性TIL的转录程序

Nature
IF48.5
2021-07-210
OAAI
Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection
2021-06-1118
OA
Targeting public neoantigens for cancer immunotherapy
2021-05-1793
OAAI
Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses
2021-05-1761
OA